<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03287518</url>
  </required_header>
  <id_info>
    <org_study_id>WOA/002017</org_study_id>
    <nct_id>NCT03287518</nct_id>
  </id_info>
  <brief_title>Evaluation of the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Analyze &amp; Realize</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Analyze &amp; Realize</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the endothelial function of WAK2017. In&#xD;
      addition the effects on the blood pressure and the parameters of lipid metabolism will be&#xD;
      explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to evaluate the endothelial function of WAK2017. In&#xD;
      addition the effects on the blood pressure and the parameters of lipid metabolism will be&#xD;
      explored.&#xD;
&#xD;
      Primary endpoint is defined as the difference in change in EndoPAT score RHI pre-dose and&#xD;
      after 12 weeks of IP intake (visit V4 vs. V2) in comparison between the verum and placebo.&#xD;
&#xD;
      To characterize the benefit of the IP the following secondary endpoints will be analysed in&#xD;
      comparison be-tween the verum and placebo:&#xD;
&#xD;
        -  EndoPAT AI at V4 vs. V2&#xD;
&#xD;
        -  SBP at V3, V4 vs. V2, respectively&#xD;
&#xD;
        -  DBP at V3, V4 vs. V2, respectively&#xD;
&#xD;
        -  Fasting LDL-C concentrations and non-HDL-C at V3, V4 vs. V2, respectively&#xD;
&#xD;
        -  Fasting TC concentrations at V3, V4 vs. V2, respec-tively&#xD;
&#xD;
        -  Fasting HDL-C concentrations at V3, V4 vs. V2, respectively&#xD;
&#xD;
        -  Fasting TG concentrations at V3, V4 vs. V2, respectively&#xD;
&#xD;
        -  Fasting LDL-C/HDL-C and TC/HDL-C ratio at V3, V4 vs. V2, respectively&#xD;
&#xD;
        -  SCORE value at V3, V4 vs. V2, respectively&#xD;
&#xD;
        -  Global evaluation of benefit by the subjects/ investigator at V4&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Anticipated">September 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, parallel-group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Endo-PAT RHI value</measure>
    <time_frame>Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2</time_frame>
    <description>Change of EndoPAT score RHI measurement Visit 2 to Visit 4. EndoPAT parameter (Reactive Hyperemia Index (RHI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EndoPAT Augmentation Index (AI)</measure>
    <time_frame>Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2</time_frame>
    <description>Change of EndoPAT parameter Augmentation Index (AI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in Systolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in Diastolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>84 weeks ± 6</time_frame>
    <description>Change in Systolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in Diastolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein cholestorol (LDL-C)</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in LDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum LDL-C concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein cholestorol (LDL-C)</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in LDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum LDL-C concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-High Density Lipoprotein cholestorol (non-HDL-C)</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in non-HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations. The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-High Density Lipoprotein cholestorol (non-HDL-C)</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in non-HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations. The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholestorol (TC)</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in TC concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholestorol (TC)</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in TC concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein cholestorol (HDL-C)</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum HDL-C concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein cholestorol (HDL-C)</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum HDL-C concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in TG concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum TG concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in TG concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum TG concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C/HDL-C ratio</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in LDL-C/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C/HDL-C ratio</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in LDL-C/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TC/HDL-C ratio</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>Change in TC/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TC/HDL-C ratio</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Change in TC/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORE Value</measure>
    <time_frame>42 days ± 3</time_frame>
    <description>The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORE Value</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of benefit</measure>
    <time_frame>84 days ± 6</time_frame>
    <description>Both the subjects and investigator(s) will evaluate independently the benefit of the IP by means of a global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endothelial Function</condition>
  <condition>Blood Pressure</condition>
  <condition>Lipid Metabolism</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.&#xD;
One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>WAK2017</intervention_name>
    <description>WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One (1) ml IP should be taken with breakfast and one (1) ml with supper every day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for WAK2017</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects, 40-75 years&#xD;
&#xD;
          2. BMI 25-34.9 kg/m2&#xD;
&#xD;
          3. High normal or hypertension grade 1 blood pressure levels (130-159 / 85-99 mmHg) both&#xD;
             at screening (mean of the 2nd and 3rd measurement during the assessment in triplicate&#xD;
             at V1) and at baseline (mean of the 2nd and 3rd measurement during the assessment in&#xD;
             triplicate at V2)&#xD;
&#xD;
          4. EndoPAT score (RHI): &lt; 2.2 at V1&#xD;
&#xD;
          5. Readiness to comply with study procedures, in particular:&#xD;
&#xD;
               -  Consumption of the IP as instructed during the treatment period&#xD;
&#xD;
               -  Adhering to former diet (except consumption of max. 2 garlic cloves per week) and&#xD;
                  physical activity&#xD;
&#xD;
               -  Requirements for blood pressure / EndoPAT measurements&#xD;
&#xD;
               -  Accepting blood draws&#xD;
&#xD;
          6. Non-smoker / smoking cessation of last ≥12 months prior to V1&#xD;
&#xD;
          7. Stable body weight in the last 3 months prior to V1 (&lt;3 kg self-reported change)&#xD;
&#xD;
          8. If allowed concomitant medications are taken this must have been stable at least&#xD;
             during the last month prior to V1&#xD;
&#xD;
          9. Women of childbearing potential:&#xD;
&#xD;
               -  Negative pregnancy testing (beta HCG-test in urine) at V1&#xD;
&#xD;
               -  Commitment to use reliable contraception methods during the study Participation&#xD;
                  is based upon written informed consent by the participant following written and&#xD;
                  oral information by the investigator regarding nature, purpose, consequences and&#xD;
                  possible risks of the clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or hypersensitivity to the components of the investigational product&#xD;
&#xD;
          2. Known genetic hyperlipidemia&#xD;
&#xD;
          3. Known secondary hypertension&#xD;
&#xD;
          4. Known white-coat hypertension&#xD;
&#xD;
          5. Known type-1-diabetes&#xD;
&#xD;
          6. Uncontrolled or within the last 6 months prior to V1 diagnosed type-2-diabetes&#xD;
&#xD;
          7. Untreated or non-stabilized thyroid disorder&#xD;
&#xD;
          8. History and/or presence of clinically significant cardiovascular disease as per&#xD;
             investigator's judgement:&#xD;
&#xD;
               -  Known congenital heart defects&#xD;
&#xD;
               -  Myocardial infarction, heart failure, angina pectoris, life-threatening&#xD;
                  arrhythmia or stroke within the last 6 months prior to V1&#xD;
&#xD;
               -  Existing thrombosis or disposition to thrombosis&#xD;
&#xD;
          9. Any other known significant or serious condition / disease that renders subjects&#xD;
             ineligible, e.g.:&#xD;
&#xD;
               -  History of malignancy within the past 5 years prior to V1&#xD;
&#xD;
               -  Bleeding disorder and/or need for anticoagulants&#xD;
&#xD;
               -  Current psychiatric care and/or use of neuroleptics&#xD;
&#xD;
               -  Bariatric surgery in the last 12 months prior to V1&#xD;
&#xD;
         10. Any known metabolic disease, gastrointestinal disorder or other clinically significant&#xD;
             disease/disorder which in the investigator's opinion could interfere with the results&#xD;
             of the study or the safety of the subject&#xD;
&#xD;
         11. Known arm lymphedema (e.g. due to mastectomy)&#xD;
&#xD;
         12. Other deviation of laboratory parameter(s) at V1 that is:&#xD;
&#xD;
               -  clinically significant or&#xD;
&#xD;
               -  2x ULN (upper limit of normal), unless the deviation is justified by a previously&#xD;
                  known not clinically relevant condition, e.g. Gilbert's syndrome)&#xD;
&#xD;
         13. Dietary habits that may interfere with the study objectives:&#xD;
&#xD;
               -  Eating disorder&#xD;
&#xD;
               -  Subjects with dietary restriction that may affect the study outcome&#xD;
&#xD;
               -  Participation in a weight loss program&#xD;
&#xD;
         14. Use of following medication/supplementation within the last 4 weeks prior to V1 and&#xD;
             during the study, according to investigator's jugdement:&#xD;
&#xD;
               -  Drugs or supplements that can influence SBP or DBP (e.g. ACE inhibitors,&#xD;
                  diuretics, calcium channel or ß-blockers, grape seed extract, coenzyme Q10 etc.)&#xD;
&#xD;
               -  Lipid lowering drugs (affecting lipid metabolism, platelet function or&#xD;
                  antioxidant status, etc.) or dietary or health supplements (e.g. omega-3 fatty&#xD;
                  acids, green tea extract, calcium, red yeast rice, phytosterols (incl. enriched&#xD;
                  products such as e.g. Becel), oat fiber, niacin, soy protein, psyllium seed husk,&#xD;
                  glucomannan, chitosan or probiotics/prebiotics)&#xD;
&#xD;
               -  Drugs that can significantly influence cholesterol levels (e.g. corticosteroids,&#xD;
                  amiodarone, anabolic steroids)&#xD;
&#xD;
               -  Medications (e.g. statins, renin angiotensin system inhibitors, nebivolol,&#xD;
                  carvedilol, calcium channel blockers) or supplements (e.g. cocoa) that can&#xD;
                  influence vascular endothelial function and/or blood flow within the last 4 weeks&#xD;
                  prior to V1 and during the study&#xD;
&#xD;
               -  Antiplatelet agents and / or anticoagulants (e.g. warfarin, acetylsalicylic acid)&#xD;
&#xD;
         15. Use of weight loss treatment&#xD;
&#xD;
         16. Drug abuse&#xD;
&#xD;
         17. Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals&#xD;
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)&#xD;
&#xD;
         18. Reported participation in night shift work 2 weeks prior to V1 and/or during the study&#xD;
&#xD;
         19. Women of child-bearing potential: pregnant or breast-feeding&#xD;
&#xD;
         20. Participation in another study or blood donation during the last 30 days prior to V1&#xD;
&#xD;
         21. Any other reason deemed suitable for exclusion as per investigator's judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Uebelhack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Ulbricht</last_name>
    <phone>0049 3040 00 8</phone>
    <phone_ext>1 62</phone_ext>
    <email>mulbricht@a-r.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masaki Matsushita, PhD</last_name>
    <phone>+ 1 949 855 2776</phone>
    <email>mmatsushita@wakunaga.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BioTeSys GmbH</name>
      <address>
        <city>Esslingen</city>
        <state>Baden Würtemberg</state>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Menzel, MD</last_name>
      <phone>0049 71135138</phone>
      <phone_ext>36</phone_ext>
      <email>m.studie@biotesys.de</email>
    </contact>
    <contact_backup>
      <last_name>Jasmin Steudle</last_name>
      <phone>004971135138</phone>
      <phone_ext>36</phone_ext>
      <email>m.studie@biotesys.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>analyze &amp; realize GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Uebelhack, MD</last_name>
      <phone>0049 3040 00 8</phone>
      <phone_ext>1 23</phone_ext>
      <email>ruebelhack@analyze-realize.com</email>
    </contact>
    <contact_backup>
      <last_name>Udo Bongartz, MD</last_name>
      <phone>0049 3040 00 8</phone>
      <phone_ext>543</phone_ext>
      <email>UBongartz@a-r.com</email>
    </contact_backup>
    <investigator>
      <last_name>Udo Bongartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://proband-in-berlin.de/</url>
    <description>Homepage for study site in Berlin</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endothelial function</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Lipid metabolism</keyword>
  <keyword>EndoPAT score RHI</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03287518
org study id: WOA/002017
nct id: NCT03287518
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The main objective of the study is to evaluate the endothelial function of WAK2017. In
      addition the effects on the blood pressure and the parameters of lipid metabolism will be
      explored.
The main objective of the study is to evaluate the endothelial function of WAK2017. In
      addition the effects on the blood pressure and the parameters of lipid metabolism will be
      explored.

      Primary endpoint is defined as the difference in change in EndoPAT score RHI pre-dose and
      after 12 weeks of IP intake (visit V4 vs. V2) in comparison between the verum and placebo.

      To characterize the benefit of the IP the following secondary endpoints will be analysed in
      comparison be-tween the verum and placebo:

        -  EndoPAT AI at V4 vs. V2

        -  SBP at V3, V4 vs. V2, respectively

        -  DBP at V3, V4 vs. V2, respectively

        -  Fasting LDL-C concentrations and non-HDL-C at V3, V4 vs. V2, respectively

        -  Fasting TC concentrations at V3, V4 vs. V2, respec-tively

        -  Fasting HDL-C concentrations at V3, V4 vs. V2, respectively

        -  Fasting TG concentrations at V3, V4 vs. V2, respectively

        -  Fasting LDL-C/HDL-C and TC/HDL-C ratio at V3, V4 vs. V2, respectively

        -  SCORE value at V3, V4 vs. V2, respectively

        -  Global evaluation of benefit by the subjects/ investigator at V4
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Randomized, double-blind, placebo-controlled, parallel-group study
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
masking description: double-blind, placebo-controlled
measure: Endo-PAT RHI value
time frame: Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
description: Change of EndoPAT score RHI measurement Visit 2 to Visit 4. EndoPAT parameter (Reactive Hyperemia Index (RHI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4
measure: EndoPAT Augmentation Index (AI)
time frame: Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
description: Change of EndoPAT parameter Augmentation Index (AI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4
measure: Systolic Blood Pressure
time frame: 42 days ± 3
description: Change in Systolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3
measure: Diastolic Blood Pressure
time frame: 42 days ± 3
description: Change in Diastolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3
measure: Systolic Blood Pressure
time frame: 84 weeks ± 6
description: Change in Systolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4
measure: Diastolic Blood Pressure
time frame: 84 days ± 6
description: Change in Diastolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4
measure: Low Density Lipoprotein cholestorol (LDL-C)
time frame: 42 days ± 3
description: Change in LDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum LDL-C concentrations.
measure: Low Density Lipoprotein cholestorol (LDL-C)
time frame: 84 days ± 6
description: Change in LDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum LDL-C concentrations.
measure: non-High Density Lipoprotein cholestorol (non-HDL-C)
time frame: 42 days ± 3
description: Change in non-HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations. The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol.
measure: non-High Density Lipoprotein cholestorol (non-HDL-C)
time frame: 84 days ± 6
description: Change in non-HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations. The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol
measure: Total Cholestorol (TC)
time frame: 42 days ± 3
description: Change in TC concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations.
measure: Total Cholestorol (TC)
time frame: 84 days ± 6
description: Change in TC concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations.
measure: High Density Lipoprotein cholestorol (HDL-C)
time frame: 42 days ± 3
description: Change in HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum HDL-C concentrations.
measure: High Density Lipoprotein cholestorol (HDL-C)
time frame: 84 days ± 6
description: Change in HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum HDL-C concentrations.
measure: Triglycerides (TG)
time frame: 42 days ± 3
description: Change in TG concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum TG concentrations.
measure: Triglycerides (TG)
time frame: 84 days ± 6
description: Change in TG concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum TG concentrations.
measure: LDL-C/HDL-C ratio
time frame: 42 days ± 3
description: Change in LDL-C/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3.
measure: LDL-C/HDL-C ratio
time frame: 84 days ± 6
description: Change in LDL-C/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4.
measure: TC/HDL-C ratio
time frame: 42 days ± 3
description: Change in TC/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3.
measure: TC/HDL-C ratio
time frame: 84 days ± 6
description: Change in TC/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4.
measure: SCORE Value
time frame: 42 days ± 3
description: The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment.
measure: SCORE Value
time frame: 84 days ± 6
description: The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment.
measure: Global Evaluation of benefit
time frame: 84 days ± 6
description: Both the subjects and investigator(s) will evaluate independently the benefit of the IP by means of a global scaled evaluation with "very good", "good", "moderate" and "poor".
arm group label: Verum
arm group type: Active Comparator
description: WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
arm group label: Placebo
arm group type: Placebo Comparator
description: The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.
One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
intervention type: Dietary Supplement
intervention name: WAK2017
description: WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
arm group label: Verum
intervention type: Dietary Supplement
intervention name: Placebo
description: One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
arm group label: Placebo
other name: Placebo for WAK2017
criteria: 
gender: All
minimum age: 40 Years
maximum age: 75 Years
healthy volunteers: No
last name: Ralf Uebelhack, MD
role: Principal Investigator
affiliation: analyze & realize GmbH
last name: Maya Ulbricht
phone: 0049 3040 00 8
phone ext: 1 62
email: mulbricht@a-r.com
last name: Masaki Matsushita, PhD
phone: + 1 949 855 2776
email: mmatsushita@wakunaga.com
facility: 
status: Not yet recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
country: Germany
url: https://proband-in-berlin.de/
description: Homepage for study site in Berlin
responsible party type: Sponsor